Rather than grimly assembling data about cancer deaths to predict outcomes in treatment, the founders of Cure51 had another idea.
Instead, the company assembles data about long term survivors of cancer, thus hoping to crack the code on what keeps people alive.
It’s now raised a €15 million Seed round led by Paris-based Sofinnova Partners.
Other investors in this round included: Hitachi Ventures GmbH, Life Extension Ventures, Xavier Niel, and Olivier Pomel, CEO, and co-founder of Datadog.
Both had previously worked in five well-known oncology centers, such as the Gustave Roussy Institute in Paris and the Vall d’Hebronin Barcelona.
ImpriMed, a California-based precision medicine startup, builds AI-powered dog cancer treatment technology that helps veterinarians identify the most suitable drugs for individual canine and feline blood cancers.
The startup, which centers on improving treatment outcomes of dogs and cats with cancer first, now aims to expand its precision medicine technology for human oncology applications.
“Also, the proven know-how acquired from developing AI algorithms in veterinary oncology streamlines the building of new predictive models in human oncology.
For human precision oncology, its AI software for multiple myeloma, a rare blood cancer, is in the process of approval, aiming to commercialize in 2025, Lim told TechCrunch.
ImpriMed’s unique strength is “the ability to develop and incorporate AI models into the personalized medicine service workflow,” according to Lim.
